• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Wolters Kluwer (ENXTAM:WKL) Teams Up With Epic As Undervalued View Gains Attention

    Simply Wall St·08/01/2026 07:31:07
    Listen to the news

    Wolters Kluwer (ENXTAM:WKL) is in focus after its Health segment announced a collaboration with Epic to embed clinical decision support, medication intelligence, and patient education tools directly into Epic workflows for resource constrained providers.

    See our latest analysis for Wolters Kluwer.

    The collaboration news lands after a volatile spell for Wolters Kluwer, with the share price at €67.88 and a 30 day share price return of 18.67% following a year to date share price decline of 22.83%. The 1 year total shareholder return is down 47.23%, suggesting short term momentum has picked up even as longer term returns remain weak.

    If partnerships like Wolters Kluwer Health's work with Epic have caught your eye, this can be a good moment to broaden your search and check out 128 healthcare AI stocks

    The sharp rebound in Wolters Kluwer after a weak year can reflect investors reassessing the business rather than a lasting shift in sentiment. The next step is to see how the current share price compares with the company’s fundamentals.

    Most Popular Narrative: 5% Undervalued

    The most followed narrative currently puts Wolters Kluwer’s fair value at €71.44, slightly above the last close of €67.88, which frames the recent price recovery in a different light.

    Some investors highlight Wolters Kluwer because it combines several qualities they may look for in a long-term investment: a resilient business model, recurring revenues, strong cash generation, and a customer base that depends on its products for mission-critical workflows.

    What makes it notable in the current context is that the market appears focused on AI-driven disruption. That risk is real and should not be ignored, but the share price reaction may be exaggerating the threat relative to the company’s actual fundamentals. In other words, the stock may be pricing in a much worse scenario than the business is currently showing.

    Read the complete narrative.

    This narrative, from Metuendus, leans heavily on Wolters Kluwer’s recurring cash generation, steady profit margins and an earnings multiple that implies a more modest outlook than its projected profitability. The fair value centers on how those margins and profits hold up against current AI concerns and whether the market gradually prices the business closer to those assumed levels.

    Result: Fair Value of €71.44 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, this hinges on Wolters Kluwer sustaining its current margins while AI tools evolve and customers avoid shifting to cheaper or in-house alternatives.

    Find out about the key risks to this Wolters Kluwer narrative.

    Next Steps

    With Wolters Kluwer presenting a mix of cautious sentiment and recovery hopes, this is a good time to move fast, test the numbers yourself, and then weigh up the 5 key rewards and 2 important warning signs

    Looking for more investment ideas beyond Wolters Kluwer?

    Wolters Kluwer can be a useful reference point, but the best opportunities often emerge when you widen your search and compare it with other focused stock ideas on the Simply Wall Street Screener.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.